Pulmonary Hypertension
An Introduction to Pulmonary Hypertension
With advancements in pulmonary hypertension (PH) pathobiology over the past 20 years, more than a dozen therapies are available for the treatment of pulmonary arterial hypertension and chronic thromboembolic PH. Efforts have focused on identifying novel pathogenic targets towards the development efficacious, disease-modifying therapies. There is currently a surge in the development of novel agents, including those to rebalance bone morphogenetic protein receptor type II (BMPR-II) signalling, stimulate soluble guanylate cyclase and inhibit the nuclear factor-kappa B (NF-κB) pathway.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever changing landscape
Our supporting partners do not constitute an endorsement of the content on this page.
Explore expert perspectives from ATS 2025 with our exclusive interview series. Discover key advances in respiratory care, including updates on COPD, ILD, ventilation strategies, and emerging therapies. Stay informed with concise, clinically relevant insights tailored for healthcare professionals on touchRESPIRATORY.
RT234 is a novel investigational therapy combining inhaled dry powder vardenafil with a proprietary oscillating inhaler, designed for rapid, on-demand relief of breathlessness in patients with pulmonary arterial hypertension (PAH). In a phase 2b CPET study, RT234 demonstrated dose-dependent improvements in peak VOâ‚‚ and dyspnea. As part of our ATS 2025 coverage, Dr Raymond Benza discusses these findings, current treatment limitations, and the next steps toward a phase III clinical trial.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
As we observe World Lung Day, it is crucial to reflect on the escalating impact of respiratory diseases across the globe. Chronic respiratory diseases — including chronic obstructive pulmonary disease (COPD), asthma, lung cancer, pulmonary hypertension, obstructive sleep apnea, and others — continue to rank among the leading causes of morbidity and mortality worldwide. The World Health Organization’s latest data underscores the persistence of the global respiratory crisis:
Welcome to the latest edition of touchREVIEWS in Respiratory & Pulmonary Diseases, which covers several hot topics in respiratory medicine, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, bronchiectasis and the ever-present subject of Coronavirus Disease 2019 (COVID-19). The ...
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, ...
INSPIRE (LTI-301 clinical trial) was a phase 3 study investigating the long-term safety and tolerability of LIQ861 in patients with pulmonary arterial hypertension (NCT03399604). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) around the ...
LIQ861 is an investigational, inhaled dry powder formulation of treprostinil delivered through a device, which currently has tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF ...
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and progressive form of pulmonary hypertension (PH) caused by blood clots that don’t dissolve in the lungs. These clots cause scar-like tissue that clogs up or narrows the small blood vessels ...
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and progressive form of pulmonary hypertension (PH) caused by blood clots that don’t dissolve in the lungs. These clots cause scar-like tissue that clogs up or narrows the small blood vessels ...
In pulmonary arterial hypertension (PAH), blood vessels in the lungs are narrowed, blocked or destroyed. The damage slows blood flow through the lungs, and blood pressure in the lung arteries rises. The current clinical trial landscape for PAH and the ...
In pulmonary arterial hypertension (PAH), blood vessels in the lungs are narrowed, blocked or destroyed. The damage slows blood flow through the lungs, and blood pressure in the lung arteries rises. How the design of clinical trials has evolved in ...
Welcome to the latest edition of touchREVIEWS in Respiratory & Pulmonary Diseases, which aims to provide insightful and topical articles relevant to the everyday practice of busy physicians. Our popular expert interviews provide a snapshot of hot topics in medicine. ...
We were delighted to speak to Dr. Vijay Balasubramanian (UCSF Fresno, Fresno, CA, USA) to learn more around the interim analysis of the EXPEDITE study (ClinicalTrials.gov Identifier: NCT03497689), which investigated whether a short course of parenteral treprostinil therapy would ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
